Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Med Care. 2008 Sep;46(9):969–975. doi: 10.1097/MLR.0b013e318179253b

Table 4.

Crude and Adjusted Association between current Celecoxib and Rofecoxib use (compared to current Non-Selective Anti-Inflammatory (NS-NSAID) use) and Acute Myocardial Infarction (AMI) using Traditional Epidemiologic Methods

Person months
of exposure		 Relative
Risk		 95% CI
Celecoxib, CCS Definition for AMI 19,196
 Age-Adjusted 2.19 1.21-3.96
 Age and Comorbidity-Adjusted* 2.06 1.05-4.07
Celecoxib, Validated Claims-Based
Outcome Definition** 		18,033
 Age-Adjusted 2.33 1.24-4.38
 Age and Comorbidity-Adjusted* 2.42 1.16-5.02
Rofecoxib, CCS Outcome Definition 11,972
 Age-Adjusted 0.84 0.35-2.00
 Age and Comorbidity-Adjusted* 0.82 0.31-2.16
Rofecoxib, Validated Claims-Based
Outcome Definition** 		11,217
 Age-Adjusted 0.95 0.39-2.33
 Age and Comorbidity-Adjusted* 0.98 0.36-2.65

CI = Confidence Interval

*

adjusted for the Charlson comorbidity index (9). Potential confounders that were screened also include all those listed in Table 1.

**

results from analysis using validated AMI definition from (10)